Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

The NCCN has added revumenib (Revuforj) to its guidelines for the treatment of patients with relapsed or refractory acute ...

Pediatric oncology is defined not only by advanced treatments but also by the depth of support provided to patients and families, according to Scott C. Borinstein, MD, PhD, medical director of ...

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median ...

In an interview with Oncology Nursing News, Kirschner, who serves as the director of program development at the Cancer ...

Specialized palliative medicine and supportive oncology advanced practice providers help create a personalized treatment experience for patients. A cancer diagnosis can bring an avalanche of ...

C, OCN, discusses how patient comorbidities and adverse effect profiles guide CDK4/6 inhibitor choice in the first-line setting.